MPSS Application Scope

Solu-Medrol is indicated for the treatment of various inflammatory and autoimmune conditions, including:

Severe allergic reactions
Asthma and chronic obstructive pulmonary disease (COPD) exacerbations
Autoimmune disorders such as systemic lupus erythematosus and rheumatoid arthritis
Acute inflammatory conditions like cerebral edema and severe skin diseases
Immunosuppressive therapy in organ transplantation

solu medrol mpss

MPSS Characteristics

Ingredients: Methylprednisolone Sodium Succinate
Properties: A white or nearly white, odorless, hygroscopic, amorphous solid
Packaging Specification: Available in various strengths: 40 mg, 125 mg, 500 mg, 1 g, and 2 g per vial
Storage: Store reconstituted solution at room temperature (15–30°C)
Expiry Date: Refer to the expiration date printed on the packaging
Executive Standard: Complies with the United States Pharmacopeia (USP) standards for injectable corticosteroids
Approval Number: FDA Application Number: NDA 011856
Date of Revision: Latest revision as of June 5, 2024
Manufacturer: Pfizer Inc.

Guidelines for the Use of MPSS

Dosage and Administration:
- Recommended Dose:
  - Dosage varies based on the specific condition being treated, the severity of the condition, and the patient’s response to therapy.
  - Typical dosing ranges from 40 mg to 1 g per day, administered intravenously or intramuscularly.
- Administration:
  - Reconstitute the powder with the provided diluent or an appropriate sterile diluent.
  - Administer via slow intravenous injection, intravenous infusion, or intramuscular injection, depending on clinical circumstances.
- Missed Dose:
  - If a dose is missed, administer as soon as possible unless it is near the time for the next dose.
  - Do not administer two doses at the same time to make up for a missed dose
Adverse Reactions:
- Common Adverse Reactions:
  - Fluid retention
  - Elevated blood pressure
  - Hyperglycemia
  - Mood swings
  - Insomnia
- Serious Adverse Reactions:
  - Increased risk of infections
  - Osteoporosis with long-term use
  - Gastrointestinal bleeding
  - Psychiatric disturbances
  - Cushingoid appearance
  - Adrenal suppression
Contraindications:
- Systemic fungal infections
- Known hypersensitivity to methylprednisolone sodium succinate or any component of the formulation
- Administration of live or live attenuated vaccines during therapy
Precautions:
- Use with caution in patients with a history of tuberculosis, peptic ulcer disease, or psychiatric disorders.
- Gradual withdrawal is recommended after prolonged therapy to prevent adrenal insufficiency.
- Monitor blood glucose levels in diabetic patients.
- Avoid abrupt discontinuation to prevent withdrawal symptoms.

MPSS Interactions

May interact with nonsteroidal anti-inflammatory drugs (NSAIDs), increasing the risk of gastrointestinal bleeding.
Concurrent use with diuretics may enhance the risk of hypokalemia.
Anticholinesterase agents may have reduced efficacy.
Live vaccines may have reduced efficacy and increased risk of adverse reactions.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.